Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volume 23, Issue 5 p. 686-689

Free Access

Validity of the General Practice Research Database

Susan S. Jick D.Sc.,

Corresponding Author

Susan S. Jick D.Sc.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421; e-mail: [email protected].Search for more papers by this author

James A. Kaye M.D., Dr.PH.,

James A. Kaye M.D., Dr.PH.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Search for more papers by this author

Catherine Vasilakis-Scaramozza M.P.H.,

Catherine Vasilakis-Scaramozza M.P.H.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Search for more papers by this author

Luis A. García Rodríguez M.D., M.Sc.,

Luis A. García Rodríguez M.D., M.Sc.

Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain

Search for more papers by this author

Ana Ruigómez M.D., Ph.D.,

Ana Ruigómez M.D., Ph.D.

Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain

Search for more papers by this author

Christoph R. Meier Ph.D., M.Sc.,

Christoph R. Meier Ph.D., M.Sc.

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Basel, Switzerland

Search for more papers by this author

Raymond G. Schlienger Ph.D.,

Raymond G. Schlienger Ph.D.

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Basel, Switzerland

Search for more papers by this author

Corri Black M.B.,

Corri Black M.B.

Department of Public Health, Medical School, Aberdeen, Scotland

Search for more papers by this author

Hershel Jick M.D.,

Hershel Jick M.D.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Search for more papers by this author

Susan S. Jick D.Sc.,

Corresponding Author

Susan S. Jick D.Sc.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421; e-mail: [email protected].Search for more papers by this author

James A. Kaye M.D., Dr.PH.,

James A. Kaye M.D., Dr.PH.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Search for more papers by this author

Catherine Vasilakis-Scaramozza M.P.H.,

Catherine Vasilakis-Scaramozza M.P.H.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Search for more papers by this author

Luis A. García Rodríguez M.D., M.Sc.,

Luis A. García Rodríguez M.D., M.Sc.

Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain

Search for more papers by this author

Ana Ruigómez M.D., Ph.D.,

Ana Ruigómez M.D., Ph.D.

Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain

Search for more papers by this author

Christoph R. Meier Ph.D., M.Sc.,

Christoph R. Meier Ph.D., M.Sc.

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Basel, Switzerland

Search for more papers by this author

Raymond G. Schlienger Ph.D.,

Raymond G. Schlienger Ph.D.

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Basel, Switzerland

Search for more papers by this author

Corri Black M.B.,

Corri Black M.B.

Department of Public Health, Medical School, Aberdeen, Scotland

Search for more papers by this author

Hershel Jick M.D.,

Hershel Jick M.D.

Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

Search for more papers by this author

First published: 16 January 2012

https://doi.org/10.1592/phco.23.5.686.32205

Citations: 434

About

PDF

Tools

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

Abstract

The United Kingdom General Practice Research Database (GPRD) is an office-based, computer-generated, medical resource designed from its inception to be used for epidemiologic research. A distinct version of the GPRD is maintained by the Boston Collaborative Drug Surveillance Program and has been the source of more than 130 scientific articles primarily addressing drug safety issues. We reviewed evidence related to the validity of the GPRD. Specifically, with our extensive experience with this automated database, we evaluated the quality and completeness of the data that it contains.

References

1 Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766–8.
10.1136/bmj.302.6779.766
CASPubMedWeb of Science®Google Scholar
2 Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347–9.
10.1002/pds.2630010607
Google Scholar
3 Kaye JA, Derby LE, Melero-Montes MM, Quinn M, Jick H. The incidence of breast cancer in the General Practice Research Database compared with national cancer registration data. Br J Cancer 2000; 83: 1556–8.
10.1054/bjoc.2000.1493
CASPubMedWeb of Science®Google Scholar
4 Meier CR, Napalkov PN, Wegmueller Y, Jefferson T, Jick H. A population-based study on incidence and risk factors for influenza and its clinical complications in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834–42.
10.1007/s100960000376
CASPubMedWeb of Science®Google Scholar
5 Jick H, Vasilakis-Scaramozza C, Jick SS. Live attenuated polio vaccine and the risk of intussusception. Br J Clin Pharmacol 2001; 52: 451–3.
10.1046/j.0306-5251.2001.aid.x
CASPubMedWeb of Science®Google Scholar
6 Kaye JA, Melero-Montes MM, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322: 460–3.
10.1136/bmj.322.7284.460
CASPubMedWeb of Science®Google Scholar
7 García-Rodríguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 88–93.
10.1097/00001648-200101000-00015
CASPubMedWeb of Science®Google Scholar
8 Ruigómez A, García-Rodríguez LA, Dev VJ, Arellano F, Raniwala J. Are schizophrenia or antipsychotic drugs a risk factor for cataracts? Epidemiology 2000; 11: 620–3.
10.1097/00001648-200011000-00002
CASPubMedWeb of Science®Google Scholar
9 Jick H, Withers JM, Dean AD. Haemophilus influenzae vaccine [letter]. Br J Gen Pract 1995; 45: 107.

CASPubMedWeb of Science®Google Scholar
10 Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310: 215–18.
10.1136/bmj.310.6974.215
PubMedWeb of Science®Google Scholar
11 Jick H, Derby LE, Gurewich V, Vasilakis C. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996; 16: 321–6.
10.1002/j.1875-9114.1996.tb02963.x
CASPubMedWeb of Science®Google Scholar
12 Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997; 17: 561–4.
10.1002/j.1875-9114.1997.tb03065.x
CASPubMedWeb of Science®Google Scholar
13 Jick H, Jick SS, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium channel blockers and risk of cancer. Lancet 1997; 349: 525–8.
10.1016/S0140-6736(97)80084-0
CASPubMedWeb of Science®Google Scholar
14 Derby LE, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000; 105: 912–16.
10.1067/mai.2000.106044
CASPubMedWeb of Science®Google Scholar
15 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93.
10.1016/S0140-6736(95)91928-7
CASPubMedWeb of Science®Google Scholar
16 World Health Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thrombo-embolism. Collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 1995; 346: 1582–8.

PubMedWeb of Science®Google Scholar
17 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593–6.
10.1016/S0140-6736(95)91929-5
CASPubMedWeb of Science®Google Scholar
18 García Rodríguez LA, Jick H. The risk of upper gastrointestinal bleeding and/or perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72.
10.1016/S0140-6736(94)91843-0
PubMedWeb of Science®Google Scholar
19 Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8.
10.1016/S0140-6736(94)90185-6
CASPubMedWeb of Science®Google Scholar
20 Pérez Gutthann S, García Rodríguez LA, Castellsague J, Oliart Duque A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796–800.
10.1136/bmj.314.7083.796
PubMedWeb of Science®Google Scholar
21 Daly E, Vessey MP, Hawkins MH, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80.
10.1016/S0140-6736(96)07113-9
CASPubMedWeb of Science®Google Scholar
22 Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiologic evidence for a causal association. Lancet 1999; 353: 2026–9.
10.1016/S0140-6736(99)01239-8
CASPubMedWeb of Science®Google Scholar
23 Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205–10.
10.1001/jama.283.24.3205
CASPubMedWeb of Science®Google Scholar
24 Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fracture in elderly patients. JAMA 2000; 283: 3211–16.
10.1001/jama.283.24.3211
CASPubMedWeb of Science®Google Scholar
25 Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185–8.
10.1016/S0140-6736(00)02400-4
CASPubMedWeb of Science®Google Scholar
26 Vainio H, Morgan G, Kleihues P. An international evaluation of the cancer-preventive potential of non-steroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 1997; 6: 749–53.

CASPubMedWeb of Science®Google Scholar
27 Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45: 608–12.
10.1046/j.1365-2125.1998.00733.x
CASPubMedWeb of Science®Google Scholar
28 Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-I study. J Natl Cancer Inst 1998; 90: 1371–88.
10.1093/jnci/90.18.1371
CASPubMedWeb of Science®Google Scholar

Citing Literature

Volume23, Issue5

May 2003

Pages 686-689

This article also appears in:

Pharmacotherapy: ACCP 40th Anniversary Issue

Validity of the General Practice Research Database

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Validity of the General Practice Research Database

Abstract

References

Citing Literature

References

Related

Information